Save the Antibiotic Xenleta as a Last Resort

Xenleta (zen-LEH-tah, lefamulin) will be the first oral and IV med in a new class of "pleuromutilin" antibiotics.

Xenleta is approved for community-acquired pneumonia. It will be touted as an option for resistant infections due to its unique mechanism.

But Xenleta doesn't seem more effective than other antibiotics.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote